Diagnosis and treatment of giant retroperitoneal paraganglioma with metastasis in children: a case report
-
摘要:
目的结合病例分析儿童巨大腹膜后副神经节瘤伴转移诊疗过程，总结儿童副神经节瘤的诊疗经验。 方法回顾性分析重庆医科大学附属儿童医院泌尿外科收治1例副神经节瘤伴远处转移患者的临床特点、诊疗经过以及预后情况。 结果副神经节瘤病例较少，在儿童更为罕见。本例患儿主要表现为血压高，偶尔头晕头痛，偶有气促。通过手术治疗处理巨大原发灶，通过化学治疗处理肺部转移灶及椎体浸润灶。 结论对伴有转移的恶性副神经节瘤，尤其是临床症状不典型并且诊断不明确的患者，如果手术治疗应明确肿瘤性质、明确肿瘤与周围组织血管的关系。术中减少触碰、尽可能保证瘤体包膜完整，是保证手术成功的关键。术后用化学治疗处理转移灶，短期效果理想，长期效果需要继续随访。 Abstract:ObjectiveTo analyze the diagnosis and treatment of a child of giant retroperitoneal paraganglioma with metastase, and summarize diagnosis and treatment experience of paraganglioma in children. MethodsWe retrospectivly analyzed the case history, diagnosis, treatment and prognosis of a case of paraganglioma with multiple metastases in urology department of children's hospital affiliated to chongqing medical university. ResultsThe main manifestations of this case were high blood pressure, occasional dizziness and headache, and occasional shortness of breath.Large primary lesions were treated with surgery, and pulmonary metastases and vertebral infiltration were treated with chemotherapy. ConclusionFor malignant paraganglioma with metastasis, especially for patients with atypical clinical symptoms and unclear diagnosis, the nature of the tumor and the relationship between the tumor and surrounding tissues and blood vessels should be clarified if surgical treatment is performed.The key to ensure the success of the operation is to reduce the touch and to ensure the integrity of the tumor capsule.Chemotherapy has a good short-term effect, but the long-term effect needed follow-up. -
Key words:
- paraganglioma /
- retroperitoneal tumor /
- diagnosis /
- treatment
-
图 1 患者CT及CTA图像
A: CTA正位；B:CTA侧位；C: 肿瘤水平位CT；D: 肿瘤矢状位CT
Figure 1. Patient CT and CTA images
-
[1] Berends A, Buitenwerf E, de KR, et al. Incidence of pheochromocy-toma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review[J]. Eur J Intern Med, 2018, 62(3): 51-8. [2] Iacobone M, Belluzzi S. Surgical approaches and results of treatment for hereditary paragangliomas[J]. Res Clin Endocrinol Metab, 2019, 122(35): 101298-307. [3] Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine[J]. Nat Rev Endocrinol, 2015, 11(2): 101-11. doi: 10.1038/nrendo.2014.188 [4] Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J]. J Clin Oncol, 2008, 26(18): 3063-72. doi: 10.1200/JCO.2007.15.4377 [5] Kiernan CM, Solórzano CC. Pheochromocytoma and paraganglioma: diagnosis,genetics,and treatment[J]. Surg Oncol Clin.N, 2016, 25(2): 119-38. doi: 10.1016/j.suronc.2016.04.002 [6] Muñoz-Largacha JA, Glocker RJ, Moalem J, et al. Incidental posterior mediastinal paraganglioma: the safe approach to management,case report[J]. Int J Surg Case Rep, 2017, 35(1): 25-8. [7] Därr, R, Ku hn, et al. Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review[J]. Endocrine, 2017, 56(3): 495-503. doi: 10.1007/s12020-017-1300-y [8] Manu P, Runge LA. Biochemical screening for pheochromo-cytoma superiority of urinary metanephrines measurements[J]. Am J Epidemiol, 1984, 120(5): 788-90. doi: 10.1093/oxfordjournals.aje.a113947 [9] Hartmut PN, Din M, William FY, et al. Pheochromocytoma and paraganglioma[J]. N Engl J Med, 2019, 381(14): 552-65. [10] Lauren F. Pheochromocytoma and paraganglioma: genetics,diagnosis, and treatment[J]. Hematol Oncol Clin North Am, 2016, 30(3): 135-50. [11] Manisha HS, Whitney SG. Neuroedocrine and adrenal tumors[OL]. NCCN guidelines, 2019. [12] Shindorf LM, Chaudhuri B, et al. Single-agent thalidomide for treatment of malignant paraganglioma of the organ of zuckerkandl[J]. Case Rep Med, 2019, 75(8): 1-4. [13] Niemeijer ND, Alblas G, van HT, et al. Chemotherapy with cyclophosphamide,vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis[J]. Clin Endocrinol (Oxf), 2014, 81(5): 642-51. doi: 10.1111/cen.12542 [14] Gulenchyn KY, Yao X, Asa SL, et al. Radionuclide therapy in neuroendocrine tumours: a systematic review[J]. Clin Oncol (R Coll Radiol), 2012, 24(9): 294-308. [15] Wfj Y. Endocrine hypertension in Melmed[C]. 2016. [16] Groeben H, Nottebaum BJ, Alesina PF, et al. Peri-operative α-receptor blockade in phaeo-chromocytoma surgery: an observational case series[J]. Br J Anaesth, 2017, 45(3): 118-29. [17] Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas[J]. J Clin Endocrinol Metab, 2007, 92(11): 3822-8. [18] Hamidi O, Young WF, Iñiguez-Ariza I, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years[J]. J Clin Endocrinol Metab, 2017, 102(9): 3296-305. doi: 10.1210/jc.2017-00992 [19] Rafat C, Zinzindohoue F, Hernigou A, et al. Peritoneal implantation of pheo-chromocytoma following tumor capsule rupture during surgery[J]. J Clin Endocrinol Metab, 2014, 51(10): 99-107. [20] Plouin PF, Amar L, Dekkers OM, et al. European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma[J]. J Endocrinol, 2016, 174(3): G1-10. [21] Crona J, David T, Karel P. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification[J]. Endocr Rev, 2017, 38(12): 489-515. -
下载:
点击查看大图
图(2)
计量
- 文章访问数: 637
- HTML全文浏览量: 328
- PDF下载量: 10
- 被引次数: 0
